Bicara Therapeutics Inc. Common Stock
$20.00
+1.8%Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -7.9).
Valuation inputs: P/E -7.9, earnings yield N/A, momentum +1.8%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -34.4%, ROIC -38.6%).
Profitability stack: net margin 0.0%, ROE -34.4%, ROIC -38.6%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +6.9%, momentum +1.8%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Bicara Therapeutics Inc. Common Stock Market vs Earnings Trajectory
Loading price and EPS data...
Bicara Therapeutics Inc. Common Stock Fair Value Envelope
No Revenue Data
BCAX has not reported any revenue values in the available annual periods.
Bicara Therapeutics Inc. Common Stock Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
BCAX has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
BCAX has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
BCAX has not reported any net profit margin values in the available annual periods.
Bicara Therapeutics Inc. Common Stock Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Bicara Therapeutics Inc. Common Stock Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Bicara Therapeutics Inc. Common Stock Street Expectations Map
Wall Street analysts project that BCAX stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 28.60, with estimates ranging from a low of 18.00 to a high of 42.00.
The consensus 1-year price target stands at 28.60, with estimates ranging from a low of 18.00 to a high of 42.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
High uncertainty. Very wide target spread indicates significant disagreement among analysts—major valuation uncertainty or transformation underway.
Risk-Reward Profile
Favorable risk-reward. Potential upside significantly exceeds downside risk, offering asymmetric return profile attractive for risk-tolerant investors.
Analyst Conviction
High uncertainty: Wide dispersion indicates analysts struggle to agree on valuation—proceed with caution and independent analysis.
Market Sentiment Insight
High risk, high reward: Substantial upside potential exists, but wide analyst disagreement signals execution risk or unclear catalysts. Thorough due diligence essential before committing capital.
Bicara Therapeutics Inc. Common Stock Insider Positioning
During the last 12 months, insiders have purchased $4.83M and sold $3.53M worth of BCAX shares, resulting in $1.30M of net buying activity.
3 Months
0
0.00
108.4K
2.25M
-2.3M
-$2.25M
3-6 Months
300.0K
4.80M
43.5K
797.08K
+4.0M
+$4.00M
6-9 Months
8.0K
30.32K
26.4K
485.45K
-455K
-$455K
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
Ra Capital Management, L.P.
Director, 10 Percent Owner:
$4.80M
Cohlhepp Ryan
Director, Officer: President And Coo
$30K
Top Sellers
Cohlhepp Ryan
Director, Officer: President And Coo
$1.16M
Hyep Ivan
Officer: Chief Financial Officer
$1.11M
Mazumdar Claire
Director, Officer: Chief Executive Officer
$1.03M
Raben David
Officer: Chief Medical Officer
$230K
Insider Activity Analysis
Net Insider Sentiment
Moderately bullish with $1.30M net buying. Insiders show cautious optimism through measured share purchases.
Buy/Sell Ratio
Positive buy/sell ratio. Buying exceeds or matches selling, indicating net positive insider sentiment.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
4 insider sellers vs. 2 buyers. More insiders selling than buying suggests cautious or negative sentiment.
No Dividend Yield Data
BCAX has not reported any dividend yield values in the available annual periods.
bcax Dividend History
Learning Layer
Related Guides
Build conviction on BCAX by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.